BDBM50097268 (R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethyl-propyl]-2-(3-biphenyl-4-yl-propyl)-N*4*-hydroxy-succinamide::CHEMBL154440
SMILES: CC(C)(C)[C@H](NC(=O)[C@H](CCCc1ccc(cc1)-c1ccccc1)CC(=O)NO)C(=O)NC(c1ccccc1)c1ccccc1
InChI Key: InChIKey=YWZDVYPIFZUSBG-FHPVIJFVSA-N
Data: 3 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stromelysin-1 (Homo sapiens (Human)) | BDBM50097268 ((R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | CHEMBL PC cid PC sid UniChem Similars | PubMed | n/a | n/a | 8.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Global Research and Development Curated by ChEMBL | Assay Description Concentration required to inhibit the catalytic domain Matrix metalloprotease-3 using Nagase fluorogenic as a substrate. | Bioorg Med Chem Lett 11: 571-4 (2001) BindingDB Entry DOI: 10.7270/Q22B8X9X | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Stromelysin-1 (Homo sapiens (Human)) | BDBM50097268 ((R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | CHEMBL PC cid PC sid UniChem Similars | Article PubMed | n/a | n/a | 8.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Pomona College Curated by ChEMBL | Assay Description Inhibition of MMP3 | Bioorg Med Chem 15: 2223-68 (2007) Article DOI: 10.1016/j.bmc.2007.01.011 BindingDB Entry DOI: 10.7270/Q2571DBD | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
72 kDa type IV collagenase (Homo sapiens (Human)) | BDBM50097268 ((R)-N*1*-[(S)-1-(Benzhydryl-carbamoyl)-2,2-dimethy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | CHEMBL PC cid PC sid UniChem Similars | PubMed | n/a | n/a | 310 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Global Research and Development Curated by ChEMBL | Assay Description Concentration required to inhibit the catalytic domain Matrix metalloprotease-2 using Nagase fluorogenic as a substrate. | Bioorg Med Chem Lett 11: 571-4 (2001) BindingDB Entry DOI: 10.7270/Q22B8X9X | |||||||||||
More data for this Ligand-Target Pair |